House panel says Medicare biosimilar payment plan will stifle innovation

Questions linger as to whether federal health care payment policies will encourage – or stifle – the entry of more biosimilars into the marketplace. Getting the biosimilar approval process right...
Source: Rheumatology News - Category: Rheumatology Source Type: research